UK markets close in 3 hours 5 minutes

BNTX Apr 2024 155.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.40000.0000 (0.00%)
As of 02:12PM EDT. Market open.
Full screen
Previous close2.4000
Expiry date2024-04-19
Day's range2.4000 - 2.4000
Contract rangeN/A
Open interest16
  • Motley Fool

    With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?

    The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) collaborated on. While the news will certainly help the pharmaceutical companies' bottom lines, it's important to look deeper to see if any of these three stocks make a solid investment today. At first glance, Pfizer's stock appears to be a screaming deal.

  • Globe Newswire

    BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

    BioNTech is initiating a Phase 1/2 clinical trial of the mRNA-based mpox vaccine program, BNT166The Coalition for Epidemic Preparedness Innovations (CEPI) commits funding of up to $90 million for the development of vaccine candidatesData generated by this partnership will contribute to CEPI’s 100 Days Mission, a global effort to accelerate the development of well-tolerated and effective vaccines against future viral threats with pandemic potentialThe partnership is part of BioNTech’s strategy to

  • Yahoo Finance

    US approval of fall boosters comes amid uptick in COVID-19 cases

    The U.S. Food and Drug Administration (FDA) approved updated COVID-19 booster shots today, setting the stage for a fall vaccine push to combat the still-circulating virus.